

Title (en)

COMPOUNDS SPECIFIC TO ADENOSINE-A1,-A2A, AND- A3-RECEPTOR AND USES THEREOF

Title (de)

FÜR ADENOSIN-A1, -A2A- UND -A3-REZEPTOREN SPEZIFISCHE VERBINDUNGEN UND DEREN VERWENDUNGEN

Title (fr)

COMPOSES SPECIFIQUES AUX RECEPTEURS DE L'ADENOSINE-A1,-A2A, ET - A3 ET LEURS UTILISATIONS

Publication

EP 1347980 A4 20050209 (EN)

Application

EP 01997029 A 20011130

Priority

- US 0145280 W 20011130
- US 72831600 A 20001201
- US 72860700 A 20001201
- US 72861600 A 20001201

Abstract (en)

[origin: WO02057267A1] This invention pertains to compounds which specifically inhibit the adenosine A1, A2A, and A3 receptors and the use of these compounds to treat a disease associated with A1, A2A, and A3 adenosine receptors in a subjects, comprising administering to the subject a therapeutically effective amount of the compounds.

IPC 1-7

C07D 487/04; A61K 31/519; A61P 5/46; A61P 11/06

IPC 8 full level

A61K 9/08 (2006.01); **A61K 31/519** (2006.01); **A61K 45/00** (2006.01); **A61P 5/46** (2006.01); **A61P 7/00** (2006.01); **A61P 9/00** (2006.01); **A61P 9/04** (2006.01); **A61P 9/06** (2006.01); **A61P 9/08** (2006.01); **A61P 11/00** (2006.01); **A61P 11/02** (2006.01); **A61P 11/06** (2006.01); **A61P 11/08** (2006.01); **A61P 13/12** (2006.01); **A61P 25/00** (2006.01); **A61P 25/16** (2006.01); **A61P 25/20** (2006.01); **A61P 25/28** (2006.01); **A61P 27/02** (2006.01); **A61P 27/06** (2006.01); **A61P 29/00** (2006.01); **A61P 37/08** (2006.01); **A61P 39/06** (2006.01); **A61P 43/00** (2006.01); **C07D 487/04** (2006.01)

IPC 8 main group level

A61K (2006.01); **A61P** (2006.01); **C07D** (2006.01)

CPC (source: EP)

A61P 5/46 (2018.01); **A61P 7/00** (2018.01); **A61P 9/00** (2018.01); **A61P 9/04** (2018.01); **A61P 9/06** (2018.01); **A61P 9/08** (2018.01); **A61P 11/00** (2018.01); **A61P 11/02** (2018.01); **A61P 11/06** (2018.01); **A61P 11/08** (2018.01); **A61P 13/12** (2018.01); **A61P 25/00** (2018.01); **A61P 25/16** (2018.01); **A61P 25/20** (2018.01); **A61P 25/28** (2018.01); **A61P 27/02** (2018.01); **A61P 27/06** (2018.01); **A61P 29/00** (2018.01); **A61P 37/08** (2018.01); **A61P 39/06** (2018.01); **A61P 43/00** (2018.01); **C07D 487/04** (2013.01)

Citation (search report)

- [A] WO 9962518 A1 19991209 - CADUS PHARMACEUTICAL CORP [US], et al
- [PX] WO 0139777 A1 20010607 - OSI PHARM INC [US]
- [E] WO 03048120 A2 20030612 - OSI PHARM INC [US], et al

Citation (examination)

- US 5780450 A 19980714 - SHADE DEBRA L [US]
- See also references of WO 02057267A1

Cited by

US5090531A; KR20170101309A

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02057267 A1 20020725; AP 1893 A 20080923; AP 2003002807 A0 20030630; AU 2002248151 B2 20080221; BR 0115847 A 20040225; CA 2430577 A1 20020725; CN 1263757 C 20060712; CN 1489590 A 20040414; CZ 20031831 A3 20040512; EA 007254 B1 20060825; EA 200300628 A1 20031225; EP 1347980 A1 20031001; EP 1347980 A4 20050209; HU P0400692 A2 20040728; HU P0400692 A3 20070928; IL 155962 A0 20031223; JP 2004517896 A 20040617; JP 4579497 B2 20101110; ME P35308 A 20110210; MX PA03004717 A 20040630; NO 20032482 D0 20030602; NO 20032482 L 20030728; NO 327207 B1 20090511; NZ 525885 A 20050128; OA 13295 A 20070413; PL 363245 A1 20041115; YU 42703 A 20060303; ZA 200303729 B 20040514

DOCDB simple family (application)

US 0145280 W 20011130; AP 2003002807 A 20011130; AU 2002248151 A 20011130; BR 0115847 A 20011130; CA 2430577 A 20011130; CN 01822460 A 20011130; CZ 20031831 A 20011130; EA 200300628 A 20011130; EP 01997029 A 20011130; HU P0400692 A 20011130; IL 15596201 A 20011130; JP 2002557944 A 20011130; ME P35308 A 20011130; MX PA03004717 A 20011130; NO 20032482 A 20030602; NZ 52588501 A 20011130; OA 1200300148 A 20011130; PL 36324501 A 20011130; YU P42703 A 20011130; ZA 200303729 A 20030514